{"organizations": [], "uuid": "f37e1aa4f182d9a0c325241954ad44a33c88735a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "news.morningstar.com", "main_image": "", "site_section": "http://news.morningstar.com/all/dow-jones/technology.aspx", "section_title": "News Archive: Technology", "url": "http://news.morningstar.com/all/dow-jones/technology/20150928368/sanofi-regeneron-get-eu-approval-for-cholesterol-drug-praluent.aspx", "country": "US", "title": "Sanofi, Regeneron Get EU Approval for Cholesterol Drug Praluent", "performance_score": 0, "site": "morningstar.com", "participants_count": 1, "title_full": "Sanofi, Regeneron Get EU Approval for Cholesterol Drug Praluent", "spam_score": 0.0, "site_type": "news", "published": "2015-09-28T03:00:00.000+03:00", "replies_count": 0, "uuid": "f37e1aa4f182d9a0c325241954ad44a33c88735a"}, "author": "morningstar.com", "url": "http://news.morningstar.com/all/dow-jones/technology/20150928368/sanofi-regeneron-get-eu-approval-for-cholesterol-drug-praluent.aspx", "ord_in_thread": 0, "title": "Sanofi, Regeneron Get EU Approval for Cholesterol Drug Praluent", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "By Inti Landauro\nPARIS--The European Commission granted Sanofi SA (SAN.FR) and Renegeron Pharmaceuticals Inc. (REG) approval to market hypercholesterolemia drug Praluent in the bloc's 28 countries, said the pharmaceutical labs, which developed the drug together.\nThe European Commission approved Praluent, also known as alirocumab, for the treatment of adult patients with primary hypercholesteromia, the two companies said.\nFrench pharmaceutical giant Sanofi is rushing to develop new drugs to replace a number of its drugs that are entering the public domain, which would allow generic drug makers to produce and sell the same drugs at a fraction of the Sanofi price, a phenomenon known as the \"patent cliff\".\nWrite to Inti Landauro at inti.landauro@wsj.com\nSubscribe to WSJ: http://online.wsj.com?mod=djnwires\n(END) 28, 2015 01:50 ET (05:50 ", "external_links": ["http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif", "http://s7.addthis.com/static/btn/sm-share-en.gif", "http://www.addthis.com/bookmark.php?v=250", "http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Unchecked.gif"], "published": "2015-09-28T03:00:00.000+03:00", "crawled": "2015-09-28T16:55:11.454+03:00", "highlightTitle": ""}